Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT02309177
Title Safety Study of Nivolumab With Nab-Paclitaxel Plus or Minus Gemcitabine in Pancreatic Cancer, Nab-Paclitaxel / Carboplatin in Stage IIIB/IV Non-Small Cell Lung Cancer or Nab-Paclitaxel in Recurrent Metastatic Breast Cancer
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors Celgene Corporation
Age Groups: adult
Covered Countries USA

Facility Status City State Zip Country Details
UC Davis Cancer Center Sacramento California 95817 United States Details
University of California Los Angeles Santa Monica California 90404 United States Details
Yale Cancer Center New Haven Connecticut 06510 United States Details
H. Lee Moffitt Cancer Center and Research Institute University of South Florida Tampa Florida 33612 United States Details
Northwestern University-NMDTI Chicago Illinois 60611 United States Details
Dana-Farber / Harvard Cancer Institute Boston Massachusetts 02114 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02215 United States Details
John Theurer Cancer Center at Hackensack University Medical Center Hackensack New Jersey 07601 United States Details
Regional Care Cancer Centers NJ Morristown New Jersey 79062 United States Details
Levine Cancer Institute Charlotte North Carolina 28204 United States Details
Oncology Hematology Care, Inc. Cincinnati Ohio 45242 United States Details
Ohio State Medical Center Columbus Ohio 43210 United States Details
University of Pennslyvania Philadelphia Pennsylvania 19104 United States Details
Seattle Cancer Center Alliance Seattle Washington 98109 United States Details
Medical College of Wisconsin Milwaukee Wisconsin 53226 United States Details
*Shaded cells indicate that there was no data available from for the field